Study of duodenal juice Analysis of the markers in the duodenal juice to detect early stage pancreatic cancer

Study of duodenal juice Analysis of the markers in the duodenal juice to detect early stage pancreatic cancer - Analysis of the markers in the duodenal juice to detect early stage pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015832

Enrollment

1200

Registered

2014-12-05

Start date

2015-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

At the beginning of the endoscopy, the duodenum is entered within a few minutes and we collect the duodenal juice. The collection of duodenal juice The duodenal juice is collected using PR-130Q cathet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1st stage: 1) Aged 50 or more 2) Patients who undergo preoperative screening upper gastrointestinal endoscopy or endoscopic ultrasonography (EUS) for the assessment of pancreatic cancer 3) Written informed consent 4) Patients without definite malignant diseases in upper gastrointestinal lesion except pancreatic cancer 5) Patients who have undergone no surgery in gastrointestinal lesion 6) Patients without malignant disease in bile duct 2nd stage: 1) Aged 50 or more 2) Patients who undergo screening upper gastrointestinal endoscopy or EUS for their pancreatic diseases. 3) The written informed consent is obtained from all the participants in this study. 4) Patients without definite malignant diseases in upper gastrointestinal lesion except pancreatic cancer 5) Patients who have undergone no surgery in gastrointestinal lesion 7) Patients without malignant disease in bile duct Control: The renal transplantation donors 1) Aged 50 or more. 2) Patients proven to have normal pancreas by CT 3) Patients who undergo screening upper gastrointestinal endoscopy for their pancreatic diseases 4) Written informed consent 5) Patients without definite malignant diseases in upper gastrointestinal lesion except pancreatic cancer 6) Patients who have undergone no surgery in gastrointestinal lesion, such as gastrectomy, pancreatoduodenectomy and so on. 7) Patients without malignant disease in bile duct The patients who undergo physical examination 1) Aged 50 or more. 2) Patients proven to have normal pancreas by EUS 3) Patients who undergo screening upper gastrointestinal endoscopy for their pancreatic diseases 4) Written informed consent 5) Patients without definite malignant diseases in upper gastrointestinal lesion except pancreatic cancer 6) Patients who have undergone no surgery in gastrointestinal lesion, such as gastrectomy, pancreatoduodenectomy and so on. 7) Patients without malignant disease in bile duct

Exclusion criteria

Exclusion criteria: 1) They have no drug hypersensitivity. 2) The doctor-in-charge figures them to be suitable for this study.

Design outcomes

Primary

Measure	Time frame
The protein levels in the duodenal juice to detect patients with stage 0/1 pancreatic cancer	—

Secondary

Measure	Time frame
The protein levels in the duodenal juice to detect pancreatic cancer and its sensitivity, The protein levels in the duodenal juice to detect pancreatic diseases	—

Countries

Japan

Contacts

Public ContactTakao Ohtsuka

Graduate School of Medical Sciences, Kyushu University Department of Surgery and Oncology

dj@cres-kyushu.or.jp092-631-2920

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026